A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

Recruiting

Phase 2

GSK mRNA VaccineA Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

Sponsor:

GlaxoSmithKline

Code:

NCT07121192

Conditions

Influenza, Human

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Flu mRNA (Formulation A)

Flu mRNA (Formulation B)

Comparator 1

Comparator 2

Comparator 3

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-20. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2025-10-10.